AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02725840 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography (CT) Scan
Description: Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months
Study NCT02725840 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary Function Test (PFT)
Description: Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
Study NCT02760238 — intervention group
Intervention type: OTHER
Intervention: Observational
Study NCT04526379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Evaluation of behavioral disorders of children with PWS by questionnaires
Study NCT04526379 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Evaluation of behavioral disorders of children with PWS by questionnaires
Study NCT04526379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t-VNS
Description: Evaluation of the influence of 6 month-stimulation by t-VNS on emotional, cognitive, and behavioral/clinical characteristics of 12 children with PWS on 30 PWS patients included.
Study NCT01555242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aneustat (OMN54)
Description: 100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
Study NCT01874015 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mesenchymal cell transplantation
Description: Mesenchymal cell transplantation in patients with Crohn's disease.
Study NCT01874015 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mesenchymal cell and fibroblast injection
Description: Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
Study NCT04559776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait analysis
Description: gait analysis with 3D optoelectronic system and surface EMG
Study NCT03047161 — intervention group
Intervention type: DEVICE
Intervention: fetal MCG
Description: assess fetal heart rate and rhythm
Study NCT04097067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Low dose radiotherapy with 20 Gy (10x2Gy)
Study NCT03609060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
Study NCT03826329 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: this is an observational study, there is no intervention in this study
Study NCT04346615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant (BHV-3500)
Description: 10 mg intranasal (IN) for 14 days
Study NCT04346615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q8h for 14 days
Study NCT01602276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal, Cathodal or Sham tDCS
Study NCT01602276 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal, Cathodal or Sham tDCS
Study NCT00337649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epothilone D
Description: ≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks
Study NCT00337649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 4mg/kg iv loading dose, followed by 2mg/kg iv weekly
Study NCT05299541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Food dish
Description: All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months~Group A - will receive a dish of food every evening by a person employed by a rescue organization for 6 months~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected .
Study NCT05299541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetric
Description: • The patient will be measured with an indirect calorimetry device (Fitmate - COSMED Srl. Rome, Italy) to assess the nutritional requirement.
Study NCT05299541 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bioimpedance
Description: • The body composition test will be performed by the Bodystat®4000 Bioimpedance Device (BIA 4000, Bodystat, UK). .
Study NCT05299541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questioners
Description: At 3 times point , in the recruit + 3 month and 6 month 3 questioners will be given:~HADS, Quality of life 36SF and FIM
Study NCT05299541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plated food dish
Description: All patients will be assessed for nutritional risk estimates (MUST) as well as a nutritional PANDORA estimate that predicts mortality, the Pandora estimate will be measured even after 3 and 6 months Group b - will receive a food dish every evening by a person employed by a rescue organization with improved appearance of a plate for 6 months.~At the end of the meal once a week~* All dishes will be photographed at the end of the meal by Android camera, iPhone~* A NUTRITION DAY success photo form will be completed and collected .
Study NCT01585896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Help Group
Description: The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, \& Steketee, 2007).
Study NCT04498806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit device monitors daily activity as a measure of physical function.
Study NCT03559972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-label facial injection
Description: Assessing if adding SkinMedica's cosmetic topical skincare regimens improves the appearance of the skin and the subject's experience, when used after pre-elected on-label facial injection
Study NCT02116270 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: 3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
Study NCT02116270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
Study NCT04019977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Home Visiting Program
Description: Brief nurse home visiting program
Study NCT03525561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide Pill
Description: Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude.
Study NCT03525561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.
Study NCT03035591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-207
Study NCT00529373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: 50 mg tablet orally once weekly (OW)
Study NCT00529373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Odanacatib
Description: 50 mg tablet orally OW
Study NCT00529373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 5600 IU orally OW
Study NCT00529373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 5600 IU orally OW
Study NCT00529373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
Study NCT00529373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
Study NCT03620201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study NCT04991441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Controlled Dietary Sodium Restriction
Description: Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
Study NCT04991441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Diet & Controlled Dietary Sodium Restriction
Description: Participants will follow a Observational Control Diet (CON) diet (Months 1-5) followed by an Controlled Dietary Sodium Restriction (INT) diet (Months 6-7).
Study NCT00881309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium
Description: TW 90mg/d
Study NCT04537052 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ven Restoration Therapy
Description: This is a novel and promising method, applied percutaneously, in the treatment of deep venous insufficiency . In this method, developed based on the effects of compression garments, a polymer consisting of cyanoacrylate and hyaluronic acid is injected, with ultrasound-guidance, percutaneously around the femoral vein. In this way, the diameter of the vein is reduced, and function is restored to the inadequately functioning valve. The procedure is also called percutaneous valvuloplasty. The underlying idea in the development of this product was that hyaluronic acid might cause an increase in connective tissue, while cyanoacrylate could serve as an exoskeleton by forming heavy tissue.
Study NCT00834288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: 1x200 mg Tramadol HCl OAD tablet daily
Study NCT00834288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl
Description: 1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
Study NCT04030299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-counter fitting
Description: In this group, pre-configured hearing aids, which simulate over-the-counter hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
Study NCT02960724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-AE105 PET/CT
Description: One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
Study NCT01228682 — intervention group
Intervention type: DRUG
Intervention: Tolvaptan
Description: Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
Study NCT02252835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: 800 mg once daily orally for four weeks
Study NCT02252835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: 40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
Study NCT02252835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: 600 mg once daily orally for four weeks
Study NCT02252835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: 80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
Study NCT02252835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg daily
Study NCT01935141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose IV Contrast
Description: A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
Study NCT01935141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Dose IV Contrast
Description: A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
Study NCT01935141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Siemens Sensation 64-MDCT scanner.
Description: The device will be used to perform CT Pulmonary Angiograms
Study NCT01935141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens Sensation 64-MDCT scanner.
Description: The device will be used to perform CT Pulmonary Angiograms
Study NCT01935141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque 320 non-ionic isoosmolar contrast agent
Description: Single Dose of Intravenous Iodixanol will be administered per CT scan.
Study NCT01935141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque 320 non-ionic isoosmolar contrast agent
Description: Single Dose of Intravenous Iodixanol will be administered per CT scan.
Study NCT02912702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2000U/m2 day5
Study NCT02912702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride liposome injection
Description: 25 mg/m2 day 1
Study NCT02912702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m2 was administered once on the first day of every week
Study NCT02912702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
Study NCT02912702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 150 mg/m2 twice weekly for 2 weeks and then weekly
Study NCT02912702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
Study NCT00594867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen - 4 grams per day + Placebo
Description: Acetaminophen - 4 grams per day + Placebo
Study NCT00594867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin - 325 mg per day + Placebo
Description: Aspirin - 325 mg per day + Placebo
Study NCT00594867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 gram per day + Aspirin 325 mg per day
Description: Acetaminophen 4 gram per day + Aspirin 325 mg per day
Study NCT03472014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE®
Description: IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose
Study NCT03711188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.
Study NCT03711188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.
Study NCT03711188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-101
Description: A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
Study NCT02287181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: short acting opiate
Study NCT02287181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: hypnotic drug
Study NCT02287181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index
Description: electroencephalograph
Study NCT03971032 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hysteroscopy
Description: Diagnostic procedure
Study NCT01241448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered Orally
Study NCT00938431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
Study NCT02734485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active Deep TMS
Description: The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT).
Study NCT02734485 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Deep TMS
Description: The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
Study NCT02764749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cranberry (poly)phenol containing supplement
Description: Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
Study NCT02764749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: cranberry (poly)phenol deprived supplement
Description: Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
Study NCT04041505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (feeding modality)
Description: The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
Study NCT04041505 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (feeding modality)
Description: The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
Study NCT01034917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg dissolved in water every 24 hours
Description: Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
Study NCT01034917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue with the same antiretroviral regimen
Description: Continue with the same antiretroviral regimen
Study NCT06028867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement
Study NCT06028867 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement
Study NCT06028867 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement
Study NCT04657159 — intervention group
Intervention type: OTHER
Intervention: Pain rehabilitation program
Description: Effect on health related quality of life och health-care consumption after rehabilitation
Study NCT02320019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching YH14618
Study NCT02320019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618
Study NCT03120091 — intervention group
Intervention type: DEVICE
Intervention: Real-time continuous blood glucose monitoring system(CGMS)
Description: A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
Study NCT02356835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APT001
Description: APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
Study NCT02356835 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
Study NCT03347994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.